We are glad to announce today that PathoQuest has obtained a GMP certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM). PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.
PathoQuesttoday announced the closing of a financing round up to €15M. This funding leverages the NGS technology in a proprietary approach to assess the viral safety and genetic characterization of biologics. It will support the development of PathoQuest’s US site (Wayne, PA), the expansion of the portfolio of NGS-based quality control (QC) tests and will accelerate its growth and market share worldwide.
PathoQuest, recipient of French Investment Program, expands NGS-based portfolio of quality control tests for biologics
PathoQuest, has been awarded €0.85M from the French Investment Program for the Future (Programme d’Investissement d’Avenir – PIA 4). This financing will enable PathoQuest to expand its range of services with NGS-based quality control (QC) tests for the genetic characterization of biologics at a GMP (Good Manufacturing Practice) grade.
Annoucement of the appointment of Eric Cazergue as Chief Financial Officer. Mr. Cazergue’s international career in finance roles within the healthcare industry will be a key asset supporting PathoQuest’s scale-up and global expansion efforts.
PathoQuest Appoints Colette Côté as Chief Portfolio Officer and General Manager of the Company’s U.S. Subsidiary
Annoucement of the appointment of Colette Côté, Ph.D. as Chief Portfolio Officer and General Manager of PathoQuest’s U.S. subsidiary located in Wayne, PA. Ms. Côté’s expertise and long history of innovating, developing, and applying tailored NGS-based assays to the biopharma biosafety testing space will further drive the expansion and growth of PathoQuest’s NGS-based services portfolio within the North American market.
PathoQuest announced that it has signed an agreement with the MIT to join the CAACB as an associate member. PathoQuest brings its 10-year experience in viral safety testing and quality control of biologics to contribute to research programs to help mitigate the risk of adventitious agent contamination in biopharmaceutical manufacturing. This collaboration is expected to translate into practical advances in this field and accelerate the adoption of NGS for the viral safety testing of biologics.